Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice.

To enhance the delivery of rhGAA (recombinant GAA, where GAA stands for acid alpha-glucosidase) to the affected muscles in Pompe disease, the carbohydrate moieties on the enzyme were remodelled to exhibit a high affinity ligand for the CI-MPR (cation-independent M6P receptor, where M6P stands for mannose 6-phosphate). This was achieved by chemically conjugating on to rhGAA, a synthetic oligosaccharide ligand bearing M6P residues in the optimal configuration for binding the receptor. The carbonyl chemistry used resulted in the conjugation of approx. six synthetic ligands on to each enzyme. The resulting modified enzyme [neo-rhGAA (modified recombinant human GAA harbouring synthetic oligosaccharide ligands)] displayed near-normal specific activity and significantly increased affinity for the CI-MPR. However, binding to the mannose receptor was unaffected despite the introduction of additional mannose residues in neo-rhGAA. Uptake studies using L6 myoblasts showed neo-rhGAA was internalized approx. 20-fold more efficiently than the unmodified enzyme. Administration of neo-rhGAA into Pompe mice also resulted in greater clearance of glycogen from all the affected muscles when compared with the unmodified rhGAA. Comparable reductions in tissue glycogen levels in the Pompe mice were realized using an approx. 8-fold lower dose of neo-rhGAA in the heart and diaphragm and an approx. 4-fold lower dose in the skeletal muscles. Treatment of older Pompe mice, which are more refractory to enzyme therapy, with 40 mg/kg neo-rhGAA resulted in near-complete clearance of glycogen from all the affected muscles as opposed to only partial correction with the unmodified rhGAA. These results demonstrate that remodelling the carbohydrate of rhGAA to improve its affinity for the CI-MPR represents a feasible approach to enhance the efficacy of enzyme replacement therapy for Pompe disease.

[1]  J. Eaton,et al.  Radiation-induced cell death: importance of lysosomal destabilization. , 2005, The Biochemical journal.

[2]  J. Schifferli,et al.  Expression of functional recombinant von Willebrand factor-A domain from human complement C2: a potential binding site for C4 and CRIT. , 2005, The Biochemical journal.

[3]  E. Herrera,et al.  Englitazone administration to late pregnant rats produces delayed body growth and insulin resistance in their fetuses and neonates. , 2005, The Biochemical journal.

[4]  H. Imai,et al.  Up-regulation of phospholipid hydroperoxide glutathione peroxidase in rat casein-induced polymorphonuclear neutrophils. , 2005, The Biochemical journal.

[5]  B. Thurberg,et al.  High-resolution Light Microscopy (HRLM) and Digital Analysis of Pompe Disease Pathology , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[6]  Qun Zhou,et al.  Conjugation of Mannose 6-Phosphate-containing Oligosaccharides to Acid α-Glucosidase Improves the Clearance of Glycogen in Pompe Mice* , 2004, Journal of Biological Chemistry.

[7]  P. Fitzpatrick,et al.  Lipoprotein Receptor Binding, Cellular Uptake, and Lysosomal Delivery of Fusions between the Receptor-associated Protein (RAP) and α-l-Iduronidase or Acid α-Glucosidase* , 2004, Journal of Biological Chemistry.

[8]  R. Howell,et al.  Pompe disease in infants and children. , 2004, The Journal of pediatrics.

[9]  W. Hop,et al.  Long-Term Intravenous Treatment of Pompe Disease With Recombinant Human -Glucosidase From Milk , 2004 .

[10]  W. Hop,et al.  Enzyme replacement therapy in late‐onset Pompe's disease: A three‐year follow‐up , 2004, Annals of neurology.

[11]  W. Sly,et al.  Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[12]  W. Sly.  Enzyme replacement therapy for lysosomal storage disorders: successful transition from concept to clinical practice. , 2004, Missouri medicine.

[13]  R. Desnick,et al.  Dexamethasone-Mediated Up-Regulation of the Mannose Receptor Improves the Delivery of Recombinant Glucocerebrosidase to Gaucher Macrophages , 2004, Journal of Pharmacology and Experimental Therapeutics.

[14]  N. Raben,et al.  Enzyme replacement therapy in the mouse model of Pompe disease. , 2003, Molecular genetics and metabolism.

[15]  S. Haley,et al.  Pompe disease and physical disability. , 2003, Developmental medicine and child neurology.

[16]  W. Hop,et al.  The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. , 2003, Pediatrics.

[17]  L. Severijnen,et al.  Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy , 2003, Muscle & nerve.

[18]  N. Raben,et al.  Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  Qun Zhou,et al.  Mannose 6-phosphate quantitation in glycoproteins using high-pH anion-exchange chromatography with pulsed amperometric detection. , 2002, Analytical biochemistry.

[20]  W. Weis,et al.  Structural Basis for Selective Recognition of Oligosaccharides by DC-SIGN and DC-SIGNR , 2001, Science.

[21]  P. Laforêt,et al.  Juvenile and adult-onset acid maltase deficiency in France: Genotype–phenotype correlation , 2001, Neurology.

[22]  P. Meikle,et al.  Conditional tissue-specific expression of the acid alpha-glucosidase (GAA) gene in the GAA knockout mice: implications for therapy. , 2001, Human molecular genetics.

[23]  J. Charrow,et al.  Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial , 2001, Genetics in Medicine.

[24]  P. Laforêt,et al.  Juvenile and adult-onset acid maltase deficiency in France , 2000, Neurology.

[25]  W. Rom,et al.  Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line. , 2000, Biochemical and biophysical research communications.

[26]  A. Vulto,et al.  Recombinant human α-glucosidase from rabbit milk in Pompe patients , 2000, The Lancet.

[27]  E. Neufeld,et al.  Purification and characterization of recombinant human alpha-N-acetylglucosaminidase secreted by Chinese hamster ovary cells. , 2000, Protein expression and purification.

[28]  R. Baxter.  Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. , 2000, American journal of physiology. Endocrinology and metabolism.

[29]  P. Visser,et al.  Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. , 1999, Human molecular genetics.

[30]  N. Raben,et al.  Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Kornfeld,et al.  Identification of Amino Acids That Modulate Mannose Phosphorylation of Mouse DNase I, a Secretory Glycoprotein* , 1999, The Journal of Biological Chemistry.

[32]  A. Reuser,et al.  Recombinant Human Acid α-Glucosidase: High Level Production in Mouse Milk, Biochemical Characteristics, Correction of Enzyme Deficiency in GSDII KO Mice , 1998 .

[33]  K. Tao,et al.  Lysine-based Structure Responsible for Selective Mannose Phosphorylation of Cathepsin D and Cathepsin L Defines a Common Structural Motif for Lysosomal Enzyme Targeting* , 1998, The Journal of Biological Chemistry.

[34]  N. Raben,et al.  Targeted Disruption of the Acid α-Glucosidase Gene in Mice Causes an Illness with Critical Features of Both Infantile and Adult Human Glycogen Storage Disease Type II* , 1998, The Journal of Biological Chemistry.

[35]  R. Desnick,et al.  Human α-galactosidase A: characterization of the N-linked oligosaccharides on the intracellular and secreted glycoforms overexpressed by Chinese hamster ovary cells , 1998 .

[36]  J. V. Van Hove,et al.  Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail. , 1998, The Journal of clinical investigation.

[37]  H. Reichmann,et al.  Adult-onset glycogen storage disease type II: phenotypic and allelic heterogeneity in German patients , 1998, Neurogenetics.

[38]  D. Holtzman,et al.  α2‐Macroglobulin Complexes with and Mediates the Endocytosis of β‐Amyloid Peptide via Cell Surface Low‐Density Lipoprotein Receptor‐Related Protein , 1997 .

[39]  S. Kornfeld,et al.  The Phosphorylation of Bovine DNase I Asn-linked Oligosaccharides Is Dependent on Specific Lysine and Arginine Residues* , 1997, The Journal of Biological Chemistry.

[40]  S. Moestrup,et al.  Megalin/gp330 mediates uptake of albumin in renal proximal tubule. , 1996, The American journal of physiology.

[41]  F. Pieper,et al.  Expression of cDNA-encoded human acid α-glucosidase in milk of transgenic mice , 1996 .

[42]  R. Brady,et al.  High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[43]  A. Reuser,et al.  Isolation and Characterisation of a Recombinant, Precursor form of Lysosomal Acid α‐Glucosidase , 1995 .

[44]  M. Binoux.  The IGF system in metabolism regulation. , 1995, Diabete & metabolisme.

[45]  F. Inagaki,et al.  N-terminal Deletion Mutants of Insulin-like Growth Factor-II (IGF-II) Show Thr and Leu Important for Binding to Insulin and IGF-I Receptors and Leu Critical for All IGF-II Functions (*) , 1995, The Journal of Biological Chemistry.

[46]  K. Tao,et al.  Lysine-based Structure in the Proregion of Procathepsin L Is the Recognition Site for Mannose Phosphorylation (*) , 1995, The Journal of Biological Chemistry.

[47]  K. Felice,et al.  Clinical Variability in Adult‐Onset Acid Maltase Deficiency: Report of Affected Sibs and Review of the Literature , 1995, Medicine.

[48]  G. Sahagian,et al.  Lysine is a common determinant for mannose phosphorylation of lysosomal proteins. , 1994, The Journal of biological chemistry.

[49]  C. V. van Noorden,et al.  Synthesis and in situ localization of lysosomal alpha-glucosidase in muscle of an unusual variant of glycogen storage disease type II. , 1993, Ultrastructural pathology.

[50]  W. Kiess,et al.  Expression of the insulin-like growth factor-II/mannose-6-phosphate receptor in multiple human tissues during fetal life and early infancy. , 1992, The Journal of clinical endocrinology and metabolism.

[51]  O. Hindsgaul,et al.  The binding specificity of high and low molecular weight phosphomannosyl receptors from bovine testes. Inhibition studies with chemically synthesized 6-O-phosphorylated oligomannosides. , 1991, The Journal of biological chemistry.

[52]  J. Perdue,et al.  The design, expression, and characterization of human insulin-like growth factor II (IGF-II) mutants specific for either the IGF-II/cation-independent mannose 6-phosphate receptor or IGF-I receptor. , 1991, The Journal of biological chemistry.

[53]  K. von Figura,et al.  Quantitation of Mr 46000 and Mr 300000 mannose 6-phosphate receptors in human cells and tissues. , 1991, Biochemistry international.

[54]  T. Baranski,et al.  Generation of a lysosomal enzyme targeting signal in the secretory protein pepsinogen , 1990, Cell.

[55]  E. M. Renkin,et al.  Influence of saline infusion on blood-tissue albumin transport. , 1989, The American journal of physiology.

[56]  S. Kornfeld,et al.  Ligand interactions of the cation-independent mannose 6-phosphate receptor. The stoichiometry of mannose 6-phosphate binding. , 1989, The Journal of biological chemistry.

[57]  I. Mellman,et al.  The biogenesis of lysosomes. , 1989, Annual review of cell biology.

[58]  E. M. Renkin,et al.  Coupling of albumin flux to volume flow in skin and muscles of anesthetized rats. , 1988, The American journal of physiology.

[59]  Y. Suzuki,et al.  Intracellular transport of acid alpha-glucosidase in human fibroblasts: evidence for involvement of phosphomannosyl receptor-independent system. , 1988, Journal of biochemistry.

[60]  E. Ginns,et al.  Glucocerebrosidase, a lysosomal enzyme that does not undergo oligosaccharide phosphorylation. , 1988, Biochimica et biophysica acta.

[61]  B. Milborrow,et al.  Stereochemistry of allene biosythesis and the formation of the acetylenic carotenoid diadinoxanthin and peridinin (C37) from neoxanthin , 1981, The Biochemical journal.

[62]  B. Milborrow,et al.  Retention of the 4-pro-R hydrogen atom of mevalonate at C-2,2' of bacterioruberin in Halobacterium halobium. , 1980, The Biochemical journal.